{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:37:03Z","timestamp":1789645023284,"version":"4.0.0"},"reference-count":48,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The TTR V142I variant associated with hereditary transthyretin amyloidosis (hATTR) is present in up to 4% of African American (AA) and 1% of Hispanic\/Latinx (HL) individuals and increases risk for heart failure. Delayed and missed diagnoses could potentiate health disparities in these populations. We evaluated whether population-based genomic screening could effectively identify individuals at risk for hATTR and prompt initiation of risk management. We identified participants of the BioMe Biobank in New York City who received TTR V142I results through a pilot genomic screening program. We performed a retrospective medical record review to evaluate for the presence hATTR-related systemic features, uptake of recommended follow-up, and short-term outcomes. Thirty-two AA (N = 17) and HL (N = 15) individuals received a TTR V142I result (median age 57, 81% female). None had a previous diagnosis of hATTR. Eighteen (56%) had hATTR-related systemic features, including 4 (13%) with heart failure, 10 (31%) with carpal tunnel syndrome, and 10 (31%) with spinal stenosis. Eighteen (56%) pursued follow-up with a cardiologist within 8 months. One person received a diagnosis of hATTR. Thus, we found that the majority of V142I-positive individuals had hATTR-related systemic features at the time of result disclosure, including well-described red flags. Genomic screening can help identify hATTR risk and guide management early on, avoiding potential delays in diagnosis and treatment.<\/jats:p>","DOI":"10.3390\/jpm11010049","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T12:44:05Z","timestamp":1610714645000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Genomic Screening Identifies Individuals at High Risk for Hereditary Transthyretin Amyloidosis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7289-1418","authenticated-orcid":false,"given":"Emily R.","family":"Soper","sequence":"first","affiliation":[{"name":"The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3333-7526","authenticated-orcid":false,"given":"Sabrina A.","family":"Suckiel","sequence":"additional","affiliation":[{"name":"The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna T.","family":"Braganza","sequence":"additional","affiliation":[{"name":"The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7400-5507","authenticated-orcid":false,"given":"Amy R.","family":"Kontorovich","sequence":"additional","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear E.","family":"Kenny","sequence":"additional","affiliation":[{"name":"The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5179-1944","authenticated-orcid":false,"given":"Noura S.","family":"Abul-Husn","sequence":"additional","affiliation":[{"name":"The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41591-020-1017-y","article-title":"Bringing monogenic disease screening to the clinic","volume":"26","author":"Murray","year":"2020","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Buchanan, A.H., Lester Kirchner, H., Schwartz, M.L.B., Kelly, M.A., Schmidlen, T., Jones, L.K., Hallquist, M.L.G., Rocha, H., Betts, M., and Schwiter, R. (2020). Clinical outcomes of a genomic screening program for actionable genetic conditions. Genet. Med.","DOI":"10.1038\/s41436-020-0876-4"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","article-title":"Population genetic screening efficiently identifies carriers of autosomal dominant diseases","volume":"26","author":"Grzymski","year":"2020","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Lemke, A.A., Amendola, L.M., Kuchta, K., Dunnenberger, H.M., Thompson, J., Johnson, C., Ilbawi, N., Oshman, L., and Hulick, P.J. (2020). Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment. J Pers. Med., 10.","DOI":"10.3390\/jpm10040165"},{"key":"ref_5","first-page":"2","article-title":"Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank","volume":"12","author":"Soper","year":"2019","journal-title":"Genome Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Abul-Husn, N.S., Manickam, K., Jones, L.K., Wright, E.A., Hartzel, D.N., Gonzaga-Jauregui, C., O\u2019Dushlaine, C., Leader, J.B., Lester Kirchner, H., and Lindbuchler, D.a.M. (2016). Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science, 354.","DOI":"10.1126\/science.aaf7000"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e182140","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/gim.2017.145","article-title":"Early cancer diagnoses through BRCA1\/2 screening of unselected adult biobank participants","volume":"20","author":"Buchanan","year":"2018","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum. Mutat."},{"key":"ref_10","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (2001). Hereditary Transthyretin Amyloidosis. GeneReviews, University of Washington, Seattle."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","article-title":"Transthyretin cardiac amyloidoses in older North Americans","volume":"60","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41431-019-0337-1","article-title":"Estimating the prevalence of allelic variants in the transthyretin gene by analysing large-scale sequencing data","volume":"27","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/mgg3.231","article-title":"The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa","volume":"4","author":"Jacobson","year":"2016","journal-title":"Mol. Genet. Genomic. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506120500107162","article-title":"A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population","volume":"12","author":"Yamashita","year":"2005","journal-title":"Amyloid"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic\/Latino Ancestry","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.nmd.2015.02.001","article-title":"Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy","volume":"25","author":"Carr","year":"2015","journal-title":"Neuromuscul. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","article-title":"Carpal tunnel syndrome and spinal canal stenosis: Harbingers of transthyretin amyloid cardiomyopathy?","volume":"108","author":"Hein","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: A common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","unstructured":"Office of the Commissioner (2020, December 20). FDA Approves New Treatments for Heart Disease Caused by A Serious Rare Disease, Transthyretin Mediated Amyloidosis, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated#:~:text=On%20May%203%2C%20the%20U.S.,approved%20treatments%20for%20ATTR%2DCM."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Abul-Husn, N.S., Soper, E.R., Braganza, G.T., Rodriguez, J.E., Zeid, N., Cullina, S., Bobo, D., Moscati, A., Merkelson, A., and Loos, R.J.F. (2021). Implementing genomic screening in diverse populations. medRxiv.","DOI":"10.1101\/2021.01.04.21249213"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Belbin, G.M., Wenric, S., Cullina, S., Glicksberg, B.S., Moscati, A., Wojcik, G.L., Shemirani, R., Beckmann, N.D., Cohain, A., and Sorokin, E.P. (2019). Towards a fine-scale population health monitoring system. bioRxiv.","DOI":"10.1101\/780668"},{"key":"ref_32","unstructured":"(2020, December 20). Tier 1 Genomics Applications and their Importance to Public Health | CDC, Available online: https:\/\/www.cdc.gov\/genomics\/implementation\/toolkit\/tier1.htm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_34","unstructured":"(2020, December 20). Sema4: A Patient-Centered Health Intelligence Company. Available online: https:\/\/sema4.com\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e01371","DOI":"10.1002\/brb3.1371","article-title":"Advances in the treatment of hereditary transthyretin amyloidosis: A review","volume":"9","author":"Gertz","year":"2019","journal-title":"Brain Behav."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Obici","year":"2016","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/538161a","article-title":"Genomics is failing on diversity","volume":"538","author":"Popejoy","year":"2016","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: An age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dungu, J.N., Papadopoulou, S.A., Wykes, K., Mahmood, I., Marshall, J., Valencia, O., Fontana, M., Whelan, C.J., Gillmore, J.D., and Hawkins, P.N. (2016). Afro-Caribbean heart failure in the United Kingdom: Cause, outcomes, and ATTR V122I cardiac amyloidosis. Circ. Heart Fail., 9.","DOI":"10.1161\/CIRCHEARTFAILURE.116.003352"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","article-title":"Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis","volume":"158","author":"Connors","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11897-019-00436-z","article-title":"Impact of genetic testing in transthyretin (ATTR) cardiac amyloidosis","volume":"16","author":"Gopal","year":"2019","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s13023-020-01633-z","article-title":"Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: A multicenter Italian consensus","volume":"15","author":"Grandis","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"key":"ref_45","unstructured":"23andMe (2020, December 20). A New 23andMe Genetic Health Risk Report Brings to Light Underdiagnosed Condition\u201423andMe Blog. Available online: https:\/\/blog.23andme.com\/health-traits\/a-new-23andme-genetic-health-risk-report-brings-to-light-underdiagnosed-condition\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Damy","year":"2019","journal-title":"Amyloid"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: The great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cell.2019.02.048","article-title":"The missing diversity in human genetic studies","volume":"177","author":"Sirugo","year":"2019","journal-title":"Cell"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/1\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:11:31Z","timestamp":1760159491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/1\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["jpm11010049"],"URL":"https:\/\/doi.org\/10.3390\/jpm11010049","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]}}}